PARP Inhibition After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer or ER/PR +, HER2 Negative With Known BRCA1/2 Mutations: Hoosier Oncology Group BRE09-146

For full description, see www.clinicaltrials.gov.

Manuscripts/Articles:

• M Kalra, Y Tong, DR Jones, T Walsh, MA Danso, CX Ma, P Silverman, M King, SS Badve, SM Perkins, KD Miller. Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer. npj Breast Cancer 7, 29 (2021). https://doi.org/10.1038/s41523-021-00240-w. See abstract.

Abstracts/Posters/Presentations:

• S. R. Malireddy, S. M. Perkins, S. S. Badve, G. W. Sledge, K. Miller. PARP inhibition after preoperative chemotherapy in patients with triple negative breast cancer (TNBC) or known BRCA1/2 mutations: Hoosier oncology group BRE09-146. Accepted as a Poster Presentation at the Trials in Progress Session at the ASCO Annual Meeting, June 4-8 2011, Chicago, IL. J Clin Oncol 29: 2011 (suppl; abstr TPS130).
  See abstract.
• S. Dwadasi, Y. Tong, T. Walsh, M.A. Danso, C.X. Ma, P.A Silverman, M.C. King, S.M. Perkins, S.S. Badve, K. Miller. Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: Hoosier Oncology Group BRE09-146. Accepted for poster discussion at the Poster Highlights Session, Breast Cancer – Triple-Negative/Cytotoxics/Local Therapy at the ASCO Annual Meeting May 30 – June 3, 2014, Chicago IL. J Clin Oncol 32:5s, 2014 (suppl; abstr 1019^).
  See abstract.
• Miller K, Tong Y, Jones DR, Walsh T, Danso MA, Ma CX, Silverman P, King MC, Badve SS, Perkins SM. Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: Final efficacy results of Hoosier Cancer Research Network BRE09-146. Accepted as Poster Presentation at General Poster Session at the ASCO Annual Meeting, May 29-June 2, 2015, Chicago IL. J Clin Oncol 33:5s, 2015 (suppl; abstr 1082).
  See abstract.